Sulfacol

Quick links to important sections

Sulfacol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulfacol

Quick Facts

Property Description
Active ingredient Sulfasalazine (SSZ)
Form Oral tablet, Delayed-release tablet, Suppository
Pharmacological class DMARD, 5-Aminosalicylate, Anti-inflammatory agent
General purpose Reduction of chronic inflammation
Origin Synthetic organic compound

What is Sulfacol: Definition and Pharmacological Class

Sulfacol is the trade name for the prescription-only drug containing the active ingredient Sulfasalazine (SSZ), an established synthetic organic compound used to manage long-term inflammatory conditions. The medicine is officially classified as an anti-inflammatory agent and is a Disease-Modifying Antirheumatic Drug (DMARD), placing it within the broader category of 5-aminosalicylates. This classification is clinically recognized for its ability to influence underlying disease processes over time, which is particularly relevant in patients dealing with chronic, immune-mediated conditions.


Composition, Origin, and Available Forms

Sulfasalazine is chemically unique because it functions as a codrug, a single molecule intentionally linking the two active components, Sulfapyridine and 5-Aminosalicylic acid (5-ASA), via an azo linkage. This differentiating composition ensures the medicine reaches the lower bowel before being broken down by intestinal bacteria, which releases both components to perform their distinct roles. The use of an enteric-coated tablet formulation is intended to prevent the release of the drug in the stomach and small intestine, optimizing delivery to the colon. Sulfacol is typically administered via the oral route in the form of a tablet or a delayed-release tablet, though a suppository is also available for rectal administration when localized treatment in the lower colon is necessary.


How Sulfasalazine Functions and Its General Purpose

The general purpose of Sulfasalazine is to achieve sustained reduction of inflammation and exert an immunomodulation effect within the body. It acts as a prodrug whose components work through a dual mechanism: one component delivers a direct anti-inflammatory effect locally, and the other is absorbed systemically to temper the immune system's overactive response. This comprehensive approach functions to control the excessive inflammatory cycles that contribute to long-term discomfort, stiffness, and internal tissue swelling, improving the patient’s overall functional capacity.

Regulatory References

  1. Disease-Modifying Antirheumatic Drug (DMARD)

What side effects are possible with Sulfacol?

Sulfacol: Possible side effects and safety information

This section outlines the adverse reactions and safety characteristics of Sulfasalazine (Sulfacol) as officially classified in government regulatory documents.

Adverse Reaction Classification

Adverse reactions are organized by frequency and the body systems they affect, reflecting the data gathered from clinical use and regulatory review.

  • Very Common Reactions: These are effects observed in more than 1 in 10 patients and typically include nausea, anorexia, abdominal discomfort, headache, and a reversible reduction in sperm count (oligospermia) in males.
  • Common Reactions: These occur in up to 1 in 10 patients and may involve effects such as vomiting, diarrhea, dizziness, fever, rash, and minor changes like leukopenia (low white blood cell count) and elevated liver enzymes.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights rare but clinically critical events. Serious adverse reactions include severe hypersensitivity conditions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as critical blood disorders like Agranulocytosis and Aplastic Anemia. The documentation also notes potential organ damage, including hepatitis and pulmonary fibrosis.

Official safety constraints state that the medicine is contraindicated in patients with a history of hypersensitivity to sulfonamides or salicylates, and in individuals with porphyria or intestinal/urinary obstruction. Caution is advised, and use is generally not recommended, in cases of severe hepatic or renal impairment. Certain gastrointestinal effects may be more pronounced at the start of treatment, while reactions like pulmonary fibrosis are associated with long-term exposure.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Sulfacol (Sulfasalazine) overdose is derived strictly from official regulatory labeling, detailing documented manifestations and mandated emergency responses.

Documented Manifestations and Serious Risk

Official labeling indicates that overdosage may present with gastrointestinal effects such as nausea, vomiting, and gastric distress, as well as central nervous system symptoms including drowsiness and convulsions. The severity of toxicity correlates directly with the total serum sulfapyridine concentration, a metabolic component of Sulfasalazine.

A primary concern is the potential for renal blockage by crystals (crystalluria) leading to anuria (absence of urine production).

Official Emergency Actions

Immediate medical attention is required upon the suspicion of overdosage. Regulatory guidance explicitly states that an individual must contact a poison control center or emergency room at once.

Management is characterized as symptomatic and supportive, as no specific antidote is known for Sulfasalazine. Procedural steps may include gastric lavage and measures to prevent crystalluria, such as alkalinizing the urine. Fluid management protocols must be adjusted based on renal status; for instance, fluids and salt must be restricted if anuria is present.

Therapeutic Uses of Sulfacol

What Sulfacol Treats: Main Uses and Benefits

Sulfacol, a medication, is commonly used to help with symptoms related to systemic imbalance that stem from various acute infections. Its therapeutic application is relevant in clinical settings that involve acute or disruptive symptom patterns.

It is considered relevant for easing symptoms linked to organ-specific functional stress, such as those involved in uncomplicated urinary tract infections (UTIs), as well as managing acute exacerbations of chronic bronchitis in adults. Additionally, it may be part of symptomatic management for certain enteric infections like shigellosis and traveler’s diarrhea, and it supports patients during episodes of heightened discomfort from a specific, serious type of pneumonia (Pneumocystis jirovecii pneumonia). This supportive relief helps maintain a sense of stability when symptoms are more noticeable.

“This medicine is commonly used across conditions presenting with acute episodes where supportive symptomatic assistance is needed.”

This assistance contributes to improved comfort during periods of heightened symptoms associated with these conditions.

Quick Fact: Relief for Symptoms that Create Noticeable Physiological Strain

Eligibility and Restrictions for Use

Official Eligibility for Sulfacol (Sulfasalazine)

The use of Sulfacol is strictly defined by official regulatory criteria, primarily based on age, known hypersensitivity, and the status of certain medical conditions. The criteria establish absolute prohibitions and conditional requirements for use.

Contraindicated Populations

The medicine is strictly contraindicated and must not be used in the following populations:

  • Infants under 2 years of age.
  • Patients with known Hypersensitivity to sulfasalazine, sulfonamides, or salicylates.
  • Individuals with Porphyria or pre-existing Intestinal or Urinary Obstruction.
  • Patients diagnosed with Severe Hepatic Impairment or Severe Renal Impairment.

Conditional and Age-Based Eligibility

Age-Related Rules: The medicine is approved for use in adults and children 6 years of age and older. Use in children under six is restricted. No special precautions are necessary for older adults, though a prolonged plasma half-life has been noted.

Conditional Use: Use requires caution or critical appraisal in patients with pre-existing G6PD Deficiency, non-severe Renal or Hepatic Damage, Blood Dyscrasias, or a history of Severe Allergy or Bronchial Asthma. The medicine is not recommended for children with Systemic Onset Juvenile Rheumatoid Arthritis (SS-JRA).

Reproductive Status: The medicine is classified as Pregnancy Category B. Use during pregnancy is conditional and should occur only if clearly needed. It is present in low levels in breast milk, and it may cause reversible infertility (oligospermia) in men.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration with Methenamine is strictly contraindicated due to the officially documented risk of crystalluria resulting from an insoluble precipitate formation.

Enzyme-Mediated and Pharmacodynamic Interactions

The medicine acts as an inhibitor of the thiopurine methyltransferase (TPMT) enzyme. This inhibition alters the metabolism of co-administered Azathioprine and 6-Mercaptopurine, leading to a formal risk of increased myelotoxicity. Regulatory documents note that combination with Cyclosporine may result in its reduced plasma concentration, which is attributed to probable cytochrome P450 induction. A pharmacodynamic risk of increased gastrointestinal adverse events is documented when co-administered with Methotrexate. Combining with NSAIDs may also increase the risk of anticoagulation and elevated serum potassium levels.

Exposure Modification and Supplement Constraints

Interactions with other substances can significantly alter drug concentrations. Co-administration formally results in reduced absorption of Digoxin, potentially leading to non-therapeutic serum levels. Certain Oral Antibiotics may reduce the efficacy of Sulfasalazine by impairing the necessary bacterial cleavage in the colon. Iron and Calcium Gluconate reduce the absorption of the medicine itself. Furthermore, Sulfasalazine formally inhibits the absorption and metabolism of Folic Acid, carrying the documented risk of deficiency. For the Live Typhoid Vaccine, an interval of at least 24 hours between administration is recommendable. The interaction profile notes that in NAT Poor Metabolizers, higher metabolite concentrations are associated with increased risk.

Mechanism of Action

The mechanism of Sulfacol (Sulfasalazine) is defined by its dual component action, resulting from its design as a prodrug that undergoes bacterial cleavage in the colon. This process releases two distinct active components—5-Aminosalicylic acid (5-ASA) and Sulfapyridine (SP)—that influence the body's inflammatory and immune pathways in a complementary manner.


Localized Reduction of Inflammatory Mediators

This domain covers the actions of 5-ASA, which is primarily responsible for the local anti-inflammatory effect. It acts as an inhibitor of key enzymes, including Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX), which are responsible for generating pro-inflammatory molecules like prostaglandins and leukotrienes. This action, coupled with the suppression of the NF-kappaB pathway, begins to modulate the biochemical environment in affected tissue.


Systemic Immunomodulation and Pathway Control

The absorbed Sulfapyridine (SP) component targets the chronic, systemic drivers of immune activity. It functions as a modulator of immune cell activity, specifically affecting T-lymphocytes and macrophages. SP achieves this by inhibiting the Cystine/Glutamate Transporter (System Xc^−) and reducing the release of critical pro-inflammatory cytokines (e.g., TNF-alpha, IL-6). This sustained modulation leads to a gradual, systemic dampening of the overactive immune response, contributing to the persistent modulation of inflammatory activity.

Dosage and Administration Information

How Sulfacol is Used: Official Administration Guidelines

Sulfacol, containing the active ingredient Sulfasalazine, is administered via two official routes: oral (using standard or delayed-release tablets) and rectal (using a suppository or enema), with the choice depending on the required location of action within the gastrointestinal tract. The usage pattern is formally defined by a titrated dosing schedule. For adult treatment of acute Ulcerative Colitis (UC), treatment typically begins with a low dose that is gradually escalated to an acute phase maximum of 4 grams per day in divided doses.

Following control of the acute phase, the regimen transitions to a long-term maintenance dose, often 2 grams per day for adults, also taken in divided doses. To ensure proper drug delivery and mitigate gastrointestinal disturbance, oral tablets are generally taken following meals with a full glass of water. A critical administration constraint is that delayed-release tablets must be swallowed whole and must not be crushed, chewed, or broken, as this is necessary for the medicine to be released in the lower bowel as intended.

Population-specific instructions mandate that dose modification may be required for patients with impaired kidney or liver function. For pediatric patients, the dose is not fixed and is instead determined based on the child's body weight (e.g., 40 to 60 mg/kg/day). The overall use protocol is defined by this structured progression from a monitored starting phase to a stable, long-term pattern, requiring strict adherence to the handling instructions to maintain the drug's intended action.

Recent Clinical Evidence

Evidence for Use in Ulcerative Colitis (UC)

Sulfacol has been studied in numerous Randomized Controlled Trials (RCTs) and meta-analyses. These studies focused on two scenarios: exploring outcomes related to reaching a status of clinical remission during active disease and examining maintenance of that status over time.

Available Study Designs for UC Remission

Studies explored outcomes related to physical discomfort and systemic imbalance, monitoring the rate of participants who met the criteria for clinical remission when compared to control groups. Research also examined long-term scenarios where studies tracked symptom recurrence over extended periods.


Evidence for Use in Rheumatoid Arthritis (RA)

Sulfacol was studied for Rheumatoid Arthritis (RA) in RCTs and comparative studies focused on adult populations. The research base includes numerous trials where the compound was evaluated against a placebo.

Measures of Disease Activity and Functional Outcomes

Research examined various patient-reported outcomes, physical assessments, and standardized composite scores to define disease severity. Findings included analysis of measured disease activity status compared to placebo. Trial reports also tracked participant withdrawals and noted differences compared to control groups.


Evidence in Special Populations and Uncertainty

Research on Juvenile Rheumatoid Arthritis (JRA) consists of smaller trials, and certainty remains low compared to adult indications. For Crohn’s Disease (CD), major regulatory bodies have not recognized this compound due to research gaps, including the lack of data concerning outcomes related to mucosal healing. For all indications, long-term outcomes remain limited beyond a couple of years, and research provides limited insight into radiological progression in RA.

Frequently Asked Questions (FAQ)

Common questions about Sulfacol (FAQ)

Q: Are there different forms of Sulfacol, like regular tablets versus delayed-release?

A: Sulfacol (sulfasalazine) is available in several forms, including standard oral tablets and delayed-release oral tablets (which are enteric-coated to dissolve later). Formulations for rectal administration (suppositories or enemas) are also available. The specific form chosen is generally dependent on the intended location of action within the body.

Q: Why might Sulfacol cause orange-yellow discoloration of urine or skin?

A: Official product information notes that Sulfacol may cause an orange-yellow discoloration of the urine or skin. This discoloration is generally noted as a harmless, expected effect, but any change in color should be mentioned to a healthcare provider to rule out other causes.

Q: Can Sulfacol affect a person's blood count, and what are the signs of this?

A: Yes, regulatory documents caution that Sulfacol can, in rare instances, lead to serious blood disorders such as agranulocytosis or aplastic anemia. Potential signs that have been reported include a sore throat, fever, unusual paleness (pallor), easy bruising (purpura), or yellowing of the skin or eyes (jaundice).

Q: What should I watch out for that could indicate a severe allergic reaction to Sulfacol?

A: Official warnings indicate that signs of a severe hypersensitivity reaction, such as Stevens-Johnson syndrome, may include a fever, swollen glands, or a spreading rash. More severe signs can involve blistering, peeling, or loosening of the skin. If any serious signs are noticed, immediate consultation with a healthcare professional is important.

Q: Does Sulfacol interact with oral contraceptive pills?

A: Regulatory documents suggest that Sulfacol (sulfasalazine) may reduce the effect of estrogen in some women. In women using estrogen-containing oral contraceptives, this interaction has been reported to potentially increase the risk of pregnancy or cause breakthrough bleeding.

Q: Can Sulfacol be taken with antacids, and if so, what is the recommended timing?

A: Official guidance suggests that if an antacid is taken to relieve discomfort, administration should typically be spaced out by at least 2 hours before or after a dose of Sulfacol. This is done to support proper absorption of Sulfacol.

Q: Is it necessary to drink extra water while taking Sulfacol?

A: Regulatory precautions advise patients to maintain adequate fluid intake while taking Sulfacol. This fluid intake is suggested to help manage the potential risk of forming drug crystals (crystalluria) or kidney stones, which is a known risk associated with the medicine.

Q: Why is Sulfacol often taken in divided doses throughout the day?

A: The total daily dose of Sulfacol is often split into smaller, more frequent doses taken throughout the day. This scheduling is a common clinical approach that may help manage or lessen the severity of undesirable effects, as certain side effects are linked to the concentration of the medicine in the body.

Q: Can Sulfacol cause dizziness, and what should be done if this occurs?

A: Dizziness is listed as a common side effect of Sulfacol. If dizziness occurs, it may be advisable to sit or lie down until the feeling passes. Caution is generally recommended regarding driving or operating machinery until the individual feels fully alert and the symptom has subsided.

Q: Can Sulfacol cause problems with the pancreas?

A: Official adverse reaction lists mention that pancreatitis (inflammation of the pancreas) has been reported as a rare side effect associated with the use of Sulfacol (sulfasalazine).

Q: What are the potential effects of Sulfacol on heart function or heart rhythm?

A: Serious side effects have been reported, and these can include effects on the heart. Patients should look out for signs like a fast or irregular heartbeat or feeling much more tired than usual, as these can be signs of potential cardiac issues that require medical assessment.

Q: Does the delayed-release formulation help reduce all gastrointestinal side effects?

A: The delayed-release (enteric-coated) tablet is designed to minimize the drug's release in the upper gastrointestinal tract. While the enteric coating is intended to mitigate many GI issues, it may not eliminate all side effects, as some effects are caused by the drug components after they are absorbed systemically.

Q: What kind of monitoring (blood tests, etc.) is typically required while on Sulfacol?

A: Frequent monitoring is a requirement of treatment, especially during the first few months. This typically includes complete blood counts (CBC with differential) and liver function tests (LFTs). Tests to assess kidney function are often included in the periodic monitoring schedule.

Q: Why do some people experience ringing in their ears (tinnitus) while taking Sulfacol?

A: Official adverse reaction reports indicate that ringing in the ears (tinnitus) has been reported as a common side effect of Sulfacol (sulfasalazine). This is a known, though infrequent, effect on the auditory system.

Q: Is Sulfacol known to cause mood changes or affect sleep?

A: Yes, regulatory reports of side effects include depression, general mental or mood changes, and issues with sleep, specifically insomnia (difficulty sleeping).

Q: Does Sulfacol affect the effectiveness of vaccines?

A: Official interaction information specifies an interaction with the Live Typhoid Vaccine, for which an interval of at least 24 hours between its administration and Sulfacol is recommended. Regulatory information specifies an interaction with the Live Typhoid Vaccine, but a general statement about all vaccines is not typically provided.

Q: Are there any foods or beverages that should be limited while taking Sulfacol?

A: While specific food interactions are not generally noted in the main labels, some sources mention that limiting a large meal, alcohol, or coffee/tea in the evening may help minimize general stomach upset or sleep disturbances.

How should Sulfacol be stored and disposed of?

Storage and Disposal of Sulfasalazine (Sulfacol)

Sulfasalazine tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and must be protected from excess heat and moisture. It is strictly required that the medicine is not frozen.

Containment and Protection

The medication must be kept in the original container with the lid tightly closed. For child safety, the product must be stored out of the sight and reach of children and safety caps should be utilized.

Official Disposal

Disposal instructions require consultation with a healthcare professional regarding unused or expired product. The medication should be discarded in accordance with local regulations and must not be released into the environment or poured down drains. It is not listed for flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulfacol found in:

A-Z Index: